JP2014503516A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014503516A5 JP2014503516A5 JP2013543356A JP2013543356A JP2014503516A5 JP 2014503516 A5 JP2014503516 A5 JP 2014503516A5 JP 2013543356 A JP2013543356 A JP 2013543356A JP 2013543356 A JP2013543356 A JP 2013543356A JP 2014503516 A5 JP2014503516 A5 JP 2014503516A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- aryl
- nhc
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 39
- 125000000217 alkyl group Chemical group 0.000 claims description 24
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 22
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 21
- 125000002947 alkylene group Chemical group 0.000 claims description 20
- 125000000623 heterocyclic group Chemical group 0.000 claims description 19
- 125000003107 substituted aryl group Chemical group 0.000 claims description 18
- 239000003112 inhibitor Substances 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 14
- 125000004450 alkenylene group Chemical group 0.000 claims description 13
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 13
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 12
- 125000004399 C1-C4 alkenyl group Chemical group 0.000 claims description 11
- 125000000304 alkynyl group Chemical group 0.000 claims description 11
- 125000003118 aryl group Chemical group 0.000 claims description 10
- 125000006557 (C2-C5) alkylene group Chemical group 0.000 claims description 8
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 8
- 108700008776 hepatitis C virus NS-5 Proteins 0.000 claims description 8
- 239000002777 nucleoside Substances 0.000 claims description 8
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 125000004419 alkynylene group Chemical group 0.000 claims description 5
- 125000000732 arylene group Chemical group 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 229940124771 HCV-NS3 protease inhibitor Drugs 0.000 claims description 4
- 102000014150 Interferons Human genes 0.000 claims description 4
- 108010050904 Interferons Proteins 0.000 claims description 4
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 4
- 229940124615 TLR 7 agonist Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 229940079322 interferon Drugs 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 4
- 229960000329 ribavirin Drugs 0.000 claims description 4
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 230000009385 viral infection Effects 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 125000005549 heteroarylene group Chemical group 0.000 claims description 3
- -1 substituted Chemical class 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 241000711549 Hepacivirus C Species 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000005551 pyridylene group Chemical group 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 4
- 208000004576 Flaviviridae Infections Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 description 4
- 241000710781 Flaviviridae Species 0.000 description 2
- 125000005724 cycloalkenylene group Chemical group 0.000 description 2
- XAHPWAQGQWVKGX-MGBMXIFSSA-N CC(C)C(C(N[C@@H](Cc1cccc(O)c1)C(N(CCC1)N[C@@H]1C(OCc1cc(/C=C/CC[C@H]([C@H]2C)OC)c[s]1)=O)=O)=O)NC2=O Chemical compound CC(C)C(C(N[C@@H](Cc1cccc(O)c1)C(N(CCC1)N[C@@H]1C(OCc1cc(/C=C/CC[C@H]([C@H]2C)OC)c[s]1)=O)=O)=O)NC2=O XAHPWAQGQWVKGX-MGBMXIFSSA-N 0.000 description 1
- YTSTXQUADYXTMD-QJOREFBCSA-N CC(C)[C@@H](C(N[C@@H](Cc1cccc(O)c1)C(N(CCC1)NC1C(O[C@H](C)c1cc(/C=C/CC[C@H](C2)OC)ccc1)=O)=O)=O)NC2=O Chemical compound CC(C)[C@@H](C(N[C@@H](Cc1cccc(O)c1)C(N(CCC1)NC1C(O[C@H](C)c1cc(/C=C/CC[C@H](C2)OC)ccc1)=O)=O)=O)NC2=O YTSTXQUADYXTMD-QJOREFBCSA-N 0.000 description 1
- XIZJVYLKZRFALP-URIPJOPDSA-N CC(C)[C@@H](C(N[C@@H](Cc1cccc(O)c1)C(N(CCC1)N[C@@H]1C(NCc1cc(CC[C@@H]([C@H](C)C(C)[C@H]2C)OC)ccc1)=O)=O)=O)NC2=O Chemical compound CC(C)[C@@H](C(N[C@@H](Cc1cccc(O)c1)C(N(CCC1)N[C@@H]1C(NCc1cc(CC[C@@H]([C@H](C)C(C)[C@H]2C)OC)ccc1)=O)=O)=O)NC2=O XIZJVYLKZRFALP-URIPJOPDSA-N 0.000 description 1
- AUWZUEKUKUVCMS-RNGFSWOKSA-N CC(C)[C@@H](C(N[C@@H](Cc1cccc(O)c1)C(N(CCC1)N[C@@H]1C(OCCCC/C=C/CC[C@H]([C@H]1C)OC)=O)=O)=O)NC1=O Chemical compound CC(C)[C@@H](C(N[C@@H](Cc1cccc(O)c1)C(N(CCC1)N[C@@H]1C(OCCCC/C=C/CC[C@H]([C@H]1C)OC)=O)=O)=O)NC1=O AUWZUEKUKUVCMS-RNGFSWOKSA-N 0.000 description 1
- WPBKXFHONNKPJX-FKVNTWOLSA-N CCOC(CC/C=C/c1cccc(COC(C(CCC2)NN2C(C(Cc2cccc(O)c2)NC([C@H](C(C)C)N2)=O)=O)=O)c1)[C@@H](C)C2=O Chemical compound CCOC(CC/C=C/c1cccc(COC(C(CCC2)NN2C(C(Cc2cccc(O)c2)NC([C@H](C(C)C)N2)=O)=O)=O)c1)[C@@H](C)C2=O WPBKXFHONNKPJX-FKVNTWOLSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 125000005717 substituted cycloalkylene group Chemical group 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000005556 thienylene group Chemical group 0.000 description 1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42207110P | 2010-12-10 | 2010-12-10 | |
US61/422,071 | 2010-12-10 | ||
PCT/US2011/064009 WO2012078915A1 (en) | 2010-12-10 | 2011-12-08 | Macrocyclic inhibitors of flaviviridae viruses |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2014503516A JP2014503516A (ja) | 2014-02-13 |
JP2014503516A5 true JP2014503516A5 (enrdf_load_stackoverflow) | 2015-01-29 |
JP5847193B2 JP5847193B2 (ja) | 2016-01-20 |
Family
ID=45464097
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013543356A Expired - Fee Related JP5847193B2 (ja) | 2010-12-10 | 2011-12-08 | フラビウイルス科ウイルスの大環状インヒビター |
Country Status (20)
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2875718A1 (en) * | 2012-06-08 | 2013-12-12 | Selcia Limited | Macrocyclic inhibitors of flaviviridae viruses |
EP2861604B1 (en) * | 2012-06-08 | 2017-03-01 | Gilead Sciences, Inc. | Macrocyclic inhibitors of flaviviridae viruses |
AR091279A1 (es) * | 2012-06-08 | 2015-01-21 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
MX2016008452A (es) * | 2013-12-23 | 2016-10-14 | Gilead Sciences Inc | Sintesis de un tripeptido macrociclico inhibidor de ns3 de virus de la hepatitis c. |
KR20170054481A (ko) | 2014-09-16 | 2017-05-17 | 길리애드 사이언시즈, 인코포레이티드 | 톨-유사 수용체 조정제의 고체 형태 |
EP3236972B1 (en) | 2014-12-26 | 2021-07-28 | Emory University | Anti-viral n4-hydroxycytidine derivatives |
PT3321265T (pt) | 2015-03-04 | 2020-07-07 | Gilead Sciences Inc | Compostos 4,6-diamino-pirido[3,2-d]pirimidina compounds e a sua utilização como moduladores de receptores do tipo toll |
US20210292327A1 (en) | 2015-08-26 | 2021-09-23 | Gilead Sciences, Inc. | Deuterated toll-like receptor modulators |
WO2017197051A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Amine-linked c3-glutarimide degronimers for target protein degradation |
WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
BR102017010009A2 (pt) | 2016-05-27 | 2017-12-12 | Gilead Sciences, Inc. | Compounds for the treatment of hepatitis b virus infection |
KR102202984B1 (ko) | 2016-05-27 | 2021-01-13 | 길리애드 사이언시즈, 인코포레이티드 | Ns5a, ns5b 또는 ns3 억제제를 사용하여 b형 간염 바이러스 감염을 치료하는 방법 |
JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
EP3507288B1 (en) | 2016-09-02 | 2020-08-26 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators |
SI3507276T1 (sl) | 2016-09-02 | 2022-01-31 | Gilead Sciences, Inc. | Spojine modulatorja toličnih receptorjev |
CR20190181A (es) | 2016-10-14 | 2019-08-21 | Prec Biosciences Inc | Meganucleasas diseñadas específicamente para el reconocimiento de secuencias en el genoma del virus de la hepatitis b. |
TWI868958B (zh) | 2017-01-31 | 2025-01-01 | 美商基利科學股份有限公司 | 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型 |
JOP20180008A1 (ar) | 2017-02-02 | 2019-01-30 | Gilead Sciences Inc | مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b |
JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
WO2018237026A1 (en) | 2017-06-20 | 2018-12-27 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
EP3672970A1 (en) | 2017-08-22 | 2020-07-01 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
PL3706762T3 (pl) | 2017-12-07 | 2025-02-10 | Emory University | N4-hydroksycytydyna i pochodne oraz związane z nimi zastosowania przeciwwirusowe |
EP3728282B1 (en) | 2017-12-20 | 2023-11-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
EP3728283B1 (en) | 2017-12-20 | 2023-11-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
CN118084940A (zh) | 2018-02-13 | 2024-05-28 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
CA3091142C (en) | 2018-02-26 | 2023-04-11 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
WO2019195181A1 (en) | 2018-04-05 | 2019-10-10 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | 2,2,─環二核苷酸 |
TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
US10899735B2 (en) | 2018-04-19 | 2021-01-26 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
TW202014193A (zh) | 2018-05-03 | 2020-04-16 | 捷克科學院有機化學與生物化學研究所 | 包含碳環核苷酸之2’3’-環二核苷酸 |
WO2020010223A1 (en) | 2018-07-06 | 2020-01-09 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
EP3818052A1 (en) | 2018-07-06 | 2021-05-12 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
KR102625712B1 (ko) | 2018-07-13 | 2024-01-19 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
AU2019366355B2 (en) | 2018-10-24 | 2022-10-13 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
IL282535B2 (en) | 2018-10-31 | 2024-05-01 | Gilead Sciences Inc | Transformed 6-azabanzimidazole compounds as HPK1 inhibitors |
CA3116347A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
US11766447B2 (en) | 2019-03-07 | 2023-09-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
CA3129011C (en) | 2019-03-07 | 2023-12-19 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
EP3934757B1 (en) | 2019-03-07 | 2023-02-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
WO2020255038A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
CA3142513A1 (en) | 2019-06-25 | 2020-12-30 | Gilead Sciences, Inc. | Flt3l-fc fusion proteins and methods of use |
WO2021011891A1 (en) | 2019-07-18 | 2021-01-21 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
US20220296619A1 (en) | 2019-08-19 | 2022-09-22 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
IL315295A (en) | 2019-09-30 | 2024-10-01 | Gilead Sciences Inc | Hbv vaccines and methods treating hbv |
CN115894606A (zh) | 2019-11-04 | 2023-04-04 | 锐新医药公司 | Ras抑制剂 |
US11608346B2 (en) | 2019-11-04 | 2023-03-21 | Revolution Medicines, Inc. | Ras inhibitors |
JP2022553857A (ja) | 2019-11-04 | 2022-12-26 | レボリューション メディシンズ インコーポレイテッド | Ras阻害剤 |
EP4567109A2 (en) | 2019-12-06 | 2025-06-11 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
CA3169348A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
MX2023001507A (es) | 2020-08-07 | 2023-03-06 | Gilead Sciences Inc | Profarmacos de analogos de nucleotidos de fosfonamida y su uso farmaceutico. |
CR20230165A (es) | 2020-09-15 | 2023-06-02 | Revolution Medicines Inc | Derivados indólicos como inhibidores de ras en el tratamiento del cáncer |
TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
EP4074317A1 (en) | 2021-04-14 | 2022-10-19 | Bayer AG | Phosphorus derivatives as novel sos1 inhibitors |
KR20240017811A (ko) | 2021-05-05 | 2024-02-08 | 레볼루션 메디슨즈, 인크. | 암의 치료를 위한 ras 억제제 |
WO2022241134A1 (en) | 2021-05-13 | 2022-11-17 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
WO2022271650A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
EP4359411A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
IL309378A (en) | 2021-06-23 | 2024-02-01 | Gilead Sciences Inc | Diacylglyercol kinase modulating compounds |
WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
CN114796193B (zh) * | 2022-05-13 | 2023-07-18 | 黑龙江八一农垦大学 | 抗牛病毒性腹泻病毒的中药单体 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6124453A (en) | 1995-07-04 | 2000-09-26 | Novartis Ag | Macrolides |
AR006514A1 (es) | 1995-07-04 | 1999-09-08 | Sandoz Ag | Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende |
CA2611151A1 (en) * | 2005-06-17 | 2006-12-28 | Novartis Ag | Use of sanglifehrin in hcv |
-
2011
- 2011-12-07 UY UY0001033775A patent/UY33775A/es not_active Application Discontinuation
- 2011-12-07 AR ARP110104596A patent/AR084217A1/es unknown
- 2011-12-08 JP JP2013543356A patent/JP5847193B2/ja not_active Expired - Fee Related
- 2011-12-08 NZ NZ612159A patent/NZ612159A/en not_active IP Right Cessation
- 2011-12-08 PT PT118056977T patent/PT2649076E/pt unknown
- 2011-12-08 KR KR1020137017607A patent/KR20140031841A/ko not_active Abandoned
- 2011-12-08 ES ES11805697.7T patent/ES2536321T3/es active Active
- 2011-12-08 WO PCT/US2011/064009 patent/WO2012078915A1/en active Application Filing
- 2011-12-08 MX MX2013006475A patent/MX2013006475A/es active IP Right Grant
- 2011-12-08 CA CA2819824A patent/CA2819824A1/en not_active Abandoned
- 2011-12-08 EA EA201390822A patent/EA026114B1/ru not_active IP Right Cessation
- 2011-12-08 AU AU2011338262A patent/AU2011338262B2/en not_active Ceased
- 2011-12-08 US US13/315,069 patent/US8513184B2/en not_active Expired - Fee Related
- 2011-12-08 EP EP11805697.7A patent/EP2649076B1/en active Active
- 2011-12-08 BR BR112013014063A patent/BR112013014063A2/pt not_active IP Right Cessation
- 2011-12-08 SI SI201130434T patent/SI2649076T1/sl unknown
- 2011-12-08 PL PL11805697T patent/PL2649076T3/pl unknown
- 2011-12-08 CN CN201180066396.4A patent/CN103403009B/zh not_active Expired - Fee Related
- 2011-12-09 TW TW100145540A patent/TWI520966B/zh not_active IP Right Cessation
-
2013
- 2013-06-04 IL IL226739A patent/IL226739A/en active IP Right Grant
- 2013-07-15 US US13/942,501 patent/US8933015B2/en not_active Expired - Fee Related